Effective immediately, INVEGA TRINZA® (paliperidone palmitate) is now reimbursed through the following public formularies: Ontario Drug Benefit program as a General Benefit with Therapeutic Notes Non-Insured Health Benefits (NIHB) program For more information on gaining access to INVEGA TRINZA®, patients and their caregivers should speak with their treating physician.
Yesterday, psychiatrist and mental health researcher Dr. Phil Tibbo appeared before the Senate Committee on Social Affairs, Science and Technology examining Bill C-45, the act that will set the course for cannabis legalization by the summer of 2018. Representing the CPA, Dr. Tibbo made several recommendations to the committee, most notably that Canadians should not be legally… Read more »
We would like to take this opportunity to congratulate two of our members who were presented awards at the 6th Annual Schizophrenia International Research Society Conference held in Florence, Italy in April 2018. Dr Ashok Malla received the award for Outstanding Clinical/Community Research. Dr Lena Palaniyappan received the Rising Star award.
It is a delight to announce that the CCEIP will present at the IEPA 11 Symposium on October 7-10 at the Westin Copley Place in Boston, Massachusetts, USA. Out of 80 symposium submissions, a stand out and fascinating topic which is highly relevant to the key themes of this years IEPA Conference, was selected to… Read more »
CCEIP members had the opportunity to present a workshop at the WPA held in Berlin in early October. Appropriate Antipsychotic Treatment Selection in Early Phase Psychosis Dr. Phil Tibbo Dr. Marc-André Roy Click here to view the slide presentation: WPA 2017 AP Selection Workshop
Faculty: Ashok Malla, MD, Rahul Manchanda, MD, Philip Tibbo, MD, Richard Williams, MD, Ridha Joober, MD Sponsor: Schizophrenia Society of Canada Foundation and Otsuka-Lundbeck Alliance In 2013, the CCEIP created an assessment tool for the prediction of relapse in early psychosis to be used in clinical settings. A multi-site study was conducted in 2016 to assess… Read more »
CCEIP members had the opportunity to present two workshops at the CPA held in Ottawa earlier this month. Click here to access the following workshop presentations: Appropriate Antipsychotic Treatment Selection in Early Phase Psychosis Dr. Phil Tibbo Dr. Marc-André Roy Dr. Howard Margolese Click here to view the slide presentation: M118 CPA 2017 AP selection… Read more »
CCEIP President Dr Phil Tibbo recently presented the CCEIP tools (including Relapse Risk Assessment, the Antipsychotic Treatment Selection tool, Initiation of Treatment for Early Phase Psychotic Disorders Order Set, OPTIMA, the Tool for Monitoring Antipsychotic Side Effects, and the iHope patient discussion tool) at the Atlantic Psychiatric Conference in Prince Edward Island. Evaluations were overwhelmingly… Read more »
The iHope tool is available in both paper and electronic formats. It is meant to serve as a resource that can be used to support the conversation with newly diagnosed patients living with schizophrenia, reinforcing that patients can live well with this chronic illness. FACULTY Thomas Hastings, MD, FRCPC Associate Clinical Professor, Department of Psychiatry, McMaster… Read more »
Faculty – Howard Margolese Sponsor – Janssen A tool for patient engagement: This tool allows for a systematic discussion about the option of LAIs with patients It helps to make LAIs a choice, rather than a punishment It is based on evidence that: Relapses worsen the long term patient trajectory The best way to avoid… Read more »